Ostfold Hospital Trust
- Address
- lock Available on a paid plan
Østfold Hospital Trust - Diverse Clinical Research Center
Østfold Hospital Trust is a comprehensive clinical research center conducting diverse therapeutic investigations across multiple medical specialties. The institution demonstrates particular expertise in autoimmune disorders, hematological conditions, and oncology, with a strong emphasis on innovative treatment strategies and precision medicine approaches.
- Immune-mediated disorders including rheumatoid arthritis, immune thrombocytopenia (ITP), and IgA nephropathy
- Cancer-associated complications and rare malignancies, including venous thromboembolism in cancer patients and metastatic prostate cancer
- Novel therapeutic interventions for pain management, addiction medicine, and metabolic disorders
- Precision medicine and biomarker-driven treatment strategies in oncology
The center is actively engaged in evaluating next-generation treatments across various medical disciplines, from therapeutic drug monitoring in rheumatologic conditions to advanced anticoagulation strategies in cancer-associated thromboembolism. Research initiatives include investigation of novel agents such as efgartigimod and rilzabrutinib for immune thrombocytopenia, abelacimab for VTE prevention, and innovative approaches to chronic low back pain with Modic changes. The institution also participates in ground-breaking precision oncology trials and demonstrates commitment to addressing complex comorbidities, including benzodiazepine dependence in opioid agonist therapy patients, as well as rare genetic conditions like heterozygous familial hypercholesterolemia.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Ostfold Hospital Trust2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ostfold Hospital Trust2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 112 other sites in Norway
Therapeutic Area Benchmark — Norway
Select a therapeutic area to compare against other sites in Norway.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Norway
Market Share
Country: Norway
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ostfold Hospital Trust
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Open-label, Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination versus Intravenous Nivolumab + Relatlimab Fixed-dose Combination in Participants with Previously Untreated Metastatic or Unresectable Melanoma | Bristol-Myers Squibb Services Unlimited Company | Phase III | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 5 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Avatrombopag | 1 | Unknown | 2025-07-01 | 2025-07-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.